Clinical Trial Update: Phase 2 Study of WGI-0301 for Advanced HCC [Phase 2]

View source ↗

Summary

This document reports an ongoing Phase 2 clinical trial evaluating WGI-0301 for advanced hepatocellular carcinoma, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• WGI-0301

Snippet

Sponsor: Zhejiang Haichang Biotech Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING